在非转移性三阴性炎症性乳腺癌中,新辅助药 pembrolizumab 和化疗对病理完整反应
F Lynce1, C Valenza2, S M Niman3
1Dana-Farber Cancer Institute, Boston, USA; Harvard Medical School, Boston, USA.
使用 pembrolizumab 的新辅助化疗免疫疗法在非转移性三阴性炎症性乳腺癌 (TN-IBC) 中实现了31.7%的病理完整反应 (pCR) 率. 这凸显了对这种侵袭性乳腺癌亚型的更好的生物标志物和治疗方法的需求.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 乳腺癌研究研究 乳腺癌研究
背景情况:
- 在非转移性三阴性炎症性乳腺癌 (TN-IBC) 中,新辅助化学免疫疗法的有效性尚未得到充分证实.
- 在关键临床试验中,IBC患者的代表性不足.
研究的目的:
- 评估非转移性TN-IBC患者中新辅助药布罗利祖马布加多剂化疗的病理完整响应 (pCR) 率.
主要方法:
- 观察性,回顾性/前性,多中心队列研究.
- 包括63名非转移性TN-IBC接受新辅助 pembrolizumab和化疗的女性患者.
- 主要终点是病理完整反应 (pCR).
主要成果:
- 这种pCR率为31.7% (20/63).
- 最常见的治疗方案是:潘布罗利祖马布,高/碳金和人环素/cyclophosphamide (61.9%).
- 在新辅助治疗期间,6.4%的患者出现了疾病进展.
结论:
- 新辅助化疗和布罗利祖马布在非转移性TN-IBC中产生了31.7%的pCR率.
- 与非IBC相比,较低的pCR表明需要预测生物标志物.
- 需要进一步的研究,以改善这种罕见的乳腺癌亚型的治疗策略.
更多相关视频
05:02Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells
Published on: February 4, 2021
07:13Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
Published on: March 26, 2014
相关概念视频
Inflammatory Response
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammatory Response II: Inflammatory Exudate and Tissue Repair
The typical wound exudate is odorless, transparent, straw-colored, thin, and watery. Exudate, however, can differ depending on the state of wound healing. Likewise, the...
Inflammatory Response I: Vascular and Cellular
Scalar and Vector Triple Products
The scalar triple product is the dot product of a vector with the cross product of two vectors....
Negative Regulator Molecules
Positive, Negative, and Zero Work
